6505--Zonisamide Capsules

The Department of Veterans Affairs National Acquisition Center has issued solicitation number 36E79726R0005 for the procurement of Zonisamide Capsules in 25 mg, 50 mg, and 100 mg strengths. This solicitation seeks to establish a firm-fixed-price, indefinite-delivery, requirements contract covering a one-year base period with four one-year option periods. The contract aims to ensure an uninterrupted supply of these pharmaceutical products to federal healthcare agencies including the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Centers. Deliveries are to be made via established pharmaceutical prime vendor programs, with products packaged in 100-count bottles. Offerors must provide the drug with its exact labeled name and a unique National Drug Code (NDC), and the contractor’s label must be exclusive on the product without any over-labeling. The procurement is conducted under FAR Part 12 as a commercial item acquisition and requires electronic submission of proposals exclusively through SAM.gov, with a submission deadline of December 30, 2025. Key compliance points include strict adherence to packaging and labeling requirements aligned with FDA regulations and federal pharmaceutical standards, ensuring quality and traceability through exclusive NDC labeling. The contract emphasizes reliability and continuous supply over price alone, suggesting a trade-off evaluation approach. Inspection responsibilities rest primarily with the contractor to guarantee conformance before delivery, with acceptance likely occurring at federal distribution centers though specifics are not delineated. No small business set-asides or socio-economic preference designations apply, and no explicit evaluation factors, weights, or certifications are disclosed in the current solicitation notice. The contracting office, located in Hines, Illinois, will oversee administration, with Christopher Carthron serving as Contract Specialist and primary point of contact. The solicitation prohibits paper submissions and over-labeling practices and underscores electronic access to all solicitation documents via sam.gov, reflecting a streamlined acquisition designed to maintain continuous pharmaceutical availability to federal healthcare entities.